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Background:  The  P2-VP8  subunit  vaccine  for  the prevention  of rotavirus  gastroenteritis  is comprised
of  a  truncated  VP8  subunit  protein  from  the rotavirus  Wa  strain  (G1[P8])  fused  to  the  tetanus  toxin  P2
epitope,  and adsorbed  on  aluminum  hydroxide  for intramuscular  administration.
Methods:  Three  groups  of  16  adults  were  randomized  to receive  three  injections  of P2-VP8  (12)  or  placebo
(4)  at  doses  of  10,  30 or 60  g  of  vaccine.  IgG and  IgA  antibodies  to P2-VP8  were  assessed  by  ELISA in
serum  and lymphocyte  supernatant  (ALS).  Serum  samples  were  tested  for neutralizing  antibodies  to
homologous  and  heterologous  strains  of rotavirus.
Results: The  vaccine  was well-tolerated.  All  vaccine  recipients  demonstrated  signiﬁcant  IgA  responses
and  all  but  one  demonstrated  IgG  responses;  in  the  60 g cohort,  geometric  mean  titers  (GMTs)  rose  70-
and  80-fold  for IgA  and  IgG,  respectively.  Homologous  neutralizing  antibody  responses  were  observed  inarenteral
on-replicating
about half  of  participants  in  all three  dose  cohorts;  in the  60 g cohort,  GMTs  against  Wa rose  from  128  to
992.  Neutralizing  antibody  responses  were  robust  to P[8]  strains,  moderate  to P[4]  strains  and  negligible
to  P[6]  strains.  ALS  IgA  responses  were dose  dependent.
Conclusions:  The  P2-VP8  subunit  vaccine  was well  tolerated  and  evoked  promising  immune  responses.
Clinical  trials  registration:  NCT01764256
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Live oral rotavirus vaccines are of great beneﬁt to infants and
oung children in developing-country populations. However, their
fﬁcacy in these populations is inferior to that demonstrated in
he developed world [1,2]. Such discrepancy in performance is
ot a unique feature of rotavirus vaccines; it has been demon-
trated with other oral, live attenuated enteric vaccines such as
hose against cholera and poliomyelitis [3]. Among the purported
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reasons for the diminished efﬁcacy are inhibition of the vaccine
virus growth by transplacentally acquired or breast-milk antibod-
ies, interference by other pathogens in the gut and gut-associated
factors, such as enteropathy, all commonly observed in developing
countries. This impediment to higher vaccine efﬁcacy for live oral
vaccines might be overcome by strategies involving parenterally
administered rotavirus vaccines [4]. Such an approach is supported
by the success of parenteral vaccines for several diseases caused
by orally transmitted pathogens including poliovirus, hepatitis A
virus, Vibrio cholera and Salmonella typhi. Jiang has summarized
indirect observations in humans that support the possibility that
parenterally-administered, non-replicating rotavirus vaccines
may  be successful, including observations derived from natural
rotavirus infection studies in infants, rotavirus challenge studies
in adult volunteers, and human rotavirus vaccine trials [5]. Fur-
ther, promising direct observations have been made in animal
studies [6–9]. The induction of high antibody titers by adjuvanted
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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arenteral injection of non-replicating vaccines may  result in
ucosal protection mediated by the induction and transudation of
ntibodies into the gut. The high titers of circulating anti-rotavirus
ntibodies transmitted transplacentally in humans appear to
oth modulate the take of live oral vaccines and be protective
gainst early rotavirus disease [10–13]. Furthermore, passively
dministered antibody may  prevent or diminish rotavirus disease
6,14]. In limited human challenge studies, the presence of high
oncentrations of neutralizing antibodies appears to be correlated
ith resistance to infection and disease [15].
Truncated VP8 subunit proteins containing most of the neutral-
zing epitopes expressed by VP4 have been shown to elicit rotavirus
eutralizing antibody responses in animals [16]. The immuno-
enicity of these VP8 proteins could be signiﬁcantly enhanced when
hey were fused with the P2 epitope of tetanus toxin, which exerts
 strong T cell helper function [17]. Immunization of neonatal
iglets with a P2-VP8-P[8] chimeric protein conferred signiﬁcant
rotection against experimental rotavirus gastroenteritis [17]. In
he present study we describe a ﬁrst in human clinical trial to eval-
ate the safety and immunogenicity of this vaccine administered
y the intramuscular route with the aim to elicit sufﬁcient anti-
ody responses to afford protection in the mucosa and circumvent
any of the purported mechanisms interfering with the efﬁcacy
f orally administered, live rotavirus vaccines in developing world
opulations.
. Materials and methods
.1. P2-VP8 vaccine
The gene sequence for the P2-VP8 protein was supplied by
. Hoshino, National Institute of Allergy and Infectious Diseases
NIAID), National Institutes of Health (NIH), Bethesda, MD [16]. A
ynthetic gene, codon optimized for Escherichia coli, was inserted
nto the pJ411 expression plasmid, which also confers kanamycin
esistance, under control of a T7 promoter (optEc2) by DNA 2.0,
enlo Park, CA. The plasmid was transfected into E. coli Bl21 (DE3),
ovagen, Billerica, MA.  Master and working seed lots, as well as the
nal vaccine, were produced at the Walter Reed Army Institute of
esearch (WRAIR), Pilot Bioproduction Facility, Silver Springs, MD.
The P2-VP8 protein was puriﬁed from physically dis-
upted cells cultured in APS Superbroth (Becton Dickenson,
ranklin Lakes, NJ) plus kanamycin, induced with isopropyl--
1-thiogalactopyronoside (0.5 mM).  The cell lysate was clariﬁed
y centrifugation, the supernatant collected and passed over a
 Sepharose FF column (GE Healthcare, Wilmington, MA)  equili-
rated in Q buffer (50 mM Tris, pH 7.5) at a ratio of 1 gram of initial
ell paste/2.5 ml  of resin. The ﬂow through which contained the P2-
P8 protein was collected, adjusted to 1 M (NH4)2SO4 and applied
o a 500 ml  Butyl 650 column (Tosoh Bioscience, Grove City, OH)
quilibrated in HIC buffer (50 mM Tris, pH 7.5, 1 M (NH4)2SO4). The
olumn was washed with one column volume of HIC buffer and the
2-VP8 protein eluted in a step-wise fashion by washing to baseline
ith HIC buffer containing 0.6 M (NH4)2SO4 followed by HIC buffer
ith 0.4 M (NH4)2SO4. P2-VP8 rich fractions were collected and
uffer exchanged against PBS pH 7.1, concentrated ﬁve-fold against
 membrane with a 10 Kdal cutoff, and brought back to the origi-
al volume in PBS, pH 7.1. This process was repeated four times in
otal. The protein concentration was determined by measuring the
alculated extinction coefﬁcient (I mg/ml  = A280 of 1.74). To remove
mall molecular weight components, the P2-VP8 containing solu-
ion was extensively diaﬁltered and ultraﬁltered against a 5 Kdal
embrane using PBS pH 7.1. This material was recirculated for 18 h
t 4 ◦C over a Q Sepharose FF column (1 ml  of resin per 5 ml  of
rotein solution), the unbound material collected and the protein (2015) 3766–3772 3767
content determined by absorbance at A280. This solution was  ster-
ile ﬁltered using a Millipack-60 0.22 m ﬁltration unit (Millipore
Corp., Billerica, MA), and aseptically ﬁlled into 3 ml glass vials.
The vaccine in ﬁnal vial form contained 428 g protein per ml
(purity of 98% as determined by size exclusion HPLC), was non-
pyrogenic (<2.4 EU/ml, by LAL testing), contained less than 100 pg
of E. coli DNA per ml,  and was sterile.
Repeated intramuscular injections of the vaccine in rabbits did
not lead to any unexpected local or system toxicity. The vaccine
was found to be stable for 18 months when stored at 4 ◦C.
2.2. Vaccine formulation
The vaccine was  adsorbed onto aluminum hydroxide adju-
vant (Alhydrogel, Brenntag Biosector, Frederikssund, Denmark)
just prior to administration as follows. A sterile, non-pyrogenic alu-
minum hydroxide stock solution was  diluted to 2.6 mg of aluminum
per ml  using sterile saline, pH 7. The vaccine was diluted to either,
40, 120 or 240 g/ml in sterile saline and equal volumes of vaccine
and aluminum hydroxide were mixed in labeled, sterile glass vials
to yield a ﬁnal protein concentration of 10, 30 or 60 g per 0.5 ml
containing 0.56 mg  of aluminum as aluminum hydroxide.
2.3. Study design
A ﬁrst in human, randomized, double-blind, placebo-controlled,
dose-escalation study was  performed in healthy, 18–45 year old
adults in Baltimore, MD,  between December 2012 and October
2013.
Human experimentation guidelines of the United States Depart-
ment of Health and Human Services were followed in the conduct
of the clinical research. Prior to initiation of the study, the protocol
was reviewed and approved by an institutional review board for
the Johns Hopkins School of Public Health and PATH. Participants
were enrolled after providing written informed consent.
2.4. Procedures
Three dose-levels of the P2-VP8 subunit vaccine were sequen-
tially tested: 10 g, 30 g and 60 g in 0.5 ml.  Cohorts of 16
individuals (12 vaccine and 4 placebo recipients) per dose level
were randomly assigned to receive three intramuscular injections
of vaccine or placebo, four weeks apart. Vaccine was admixed with
0.56 mg  of aluminum hydroxide on the day of vaccination, as noted
above.
To evaluate vaccine tolerability, participants were provided
with memory aids to assess and record local and systemic reacto-
genicity during the 7 days after each vaccination, and participants
were seen 7 and 28 days after each vaccination for safety evaluation.
In addition, participants were contacted six months after the ﬁnal
vaccination to inquire about new chronic health conditions, serious
health events or hospitalizations since the last visit. Monitoring lab-
oratory assessments were performed at baseline and 7 days after
each injection. A safety review committee assessed clinical and lab-
oratory safety data for the week after the ﬁrst injection of the ﬁrst
four participants in the lowest dose cohort before proceeding to
enrolling the balance of that cohort. Similar assessment was per-
formed for the safety data from the week after the ﬁrst injection of
the two  lower dose cohorts before proceeding to the next higher
dose level, and before proceeding to subsequent injections within
each dose cohort.Serum samples were obtained at baseline and 28 days after each
injection to assess IgG and IgA responses to the P2-VP8 antigen
by ELISA and neutralizing antibody to homologous and heterolo-
gous rotavirus strains, and at baseline and 7 days after the ﬁrst
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Table 1
Maximum reactogenicity per participanta
Parameter None N (%) Mild N (%) Moderate N (%)
Injection site Pain Placebo
10 g
30 g
60 g
10(83.3)
6 (50.0)
10 (83.3)
8 (66.7)
1(8.3)
5 (41.7)
2 (16.7)
3 (25.0)
1(8.3)
1 (8.3)
0
1  (8.3)
Tenderness Placebo
10 g
30 g
60 g
8(66.7)
5 (41.7)
7 (58.3)
4 (33.3)
3(25.0)
6 (50.0)
5 (41.7)
8 (66.7)
1(8.3)
1 (8.3)
0
0
Itching  Placebo
10 g
30 g
60 g
9(75.0)
11 (91.7)
11 (91.7)
11 (91.7)
3(25.0)
1 (8.3)
1 (8.3)
1 (8.3)
0
0
0
0
Redness Placebo
10 g
30 g
60 g
11(91.7)
11 (91.7)
11 (91.7)
9 (75.0)
1(8.3)
1 (8.3)
1 (8.3)
3 (25.0)
0
0
0
0
Swelling Placebo
10 g
30 g
60 g
11(91.7)
10 (83.3)
10 (83.3)
10 (83.3)
0
2(16.7)
2 (16.7)
2 (16.7)
1(8.3)
0
0
0
Systemic Fever Placebo
10 g
30 g
60 g
12(100.0)
12 (100.0)
12 (100.0)
12 (100.0)
0
0
0
0
0
0
0
0
Nausea Placebo
10 g
30 g
60 g
10(83.3)
11 (91.7)
12 (100.0)
10 (83.3)
2(16.7)
1 (8.3)
0
2 (16.7)
0
0
0
0
Vomiting Placebo
10 g
30 g
60 g
12(100.0)
11 (91.7)
12 (100.0)
12 (100.0)
0
1(8.3)
0
0
0
0
0
0
Arthralgia Placebo
10 g
30 g
60 g
10(83.3)
11 (91.7)
11 (91.7)
9 (75.0)
2(16.7)
1 (8.3)
1 (8.3)
3 (25.0)
0
0
0
0
Chills  Placebo
10 g
30 g
60 g
11(91.7)
11 (91.7)
11 (91.7)
11 (91.7)
1(8.3)
1 (8.3)
1 (8.3)
1 (8.3)
0
0
0
0
Fatigue Placebo
10 g
30 g
60 g
10(83.3)
9 (75.0)
11 (91.7)
10 (83.3)
1(8.3)
2 (16.7)
1 (8.3)
1 (8.3)
1(8.3)
1 (8.3)
0
1  (8.3)
Headache Placebo
10 g
30 g
60 g
10(83.3)
10 (83.3)
10 (83.3)
9 (75.0)
2(16.7)
2 (16.7)
2 (16.7)
3 (25.0)
0
0
0
0
Myalgia Placebo
10 g
30 g
60 g
11(91.7)
10 (83.3)
11 (91.7)
9 (75.0)
1(8.3)
2 (16.7)
1 (8.3)
3 (25.0)
0
0
0
0
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oa No severe reactogenicity was  observed in any participants.
njection to assess antibody to the P2-VP8 antigen in lymphocyte
upernatant (ALS).
.5. Laboratory methods
Anti-P2-VP8 immunoglobulin G (IgG) and IgA antibody were
uantitated using standard ELISA assay techniques. Although the
ntigen used for the IgA and IgG assays is the P2-VP8 vaccine itself,
ot VP8 alone, competitive binding assays indicated that the P2
omponent does not contribute to the binding responses (data not
hown).
A reference standard containing pooled sera from subjects
nown to have had a natural rotavirus infection was  used for both
nti-P2-VP8 IgG and anti-P2-VP8 IgA. The reference standard was
ssigned a value of 10,000 units/mL of anti-P2-VP8 speciﬁc IgG
r IgA. The standard curve was modeled using a four parameterlogistic regression function in the SoftMax software for the ELISA
reader. The concentration of anti-P2-VP8 speciﬁc IgG or IgA in
a sample was derived by extrapolation from the reference stan-
dard curve. The lower limit of detection was  determined during
qualiﬁcation of the assay to be 8.72 and 15.15 units per mL  for
anti-P2-VP8 IgA and IgG, respectively.
Neutralizing antibody to Wa  (G1P[8]), 89-12 (G1P[8]), DS-1
(G2P[4]), P (G3P[8]), ST3 (G4P[6]), WI61 (G9P[8]), SC2 G2 P[6]) and
BrB (G4P[6]) was determined using previously described methods
[18]. Titer is deﬁned as the reciprocal of the serum dilution that
resulted in a 60% reduction in virus.
ALS were obtained by culturing peripheral blood mononuclear
cells (PBMCs) for 72 h in the absence of P2-VP8 antigen as described
[19]. The supernatant of the culture was  collected after low speed
centrifugation and tested in the same ELISA assay used for serolog-
ical evaluations.
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Table  2
Unsolicited adverse events (maximal severity per participant).
Study product Mild Moderate Severe Any
Placebo 5 (41.7%) 1 (8.3%) 0 6 (50.0%)
10  g 6 (50.0%) 3 (25.0%) 0 9 (75.0%)
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a >four-fold increase. Among the 19 participants with intermedi-
T
N30  g 2 (16.7%) 3 (25.0%) 0 5 (41.7%)
60  g 6 (50.0%) 0 1 (8.3%) 7 (58.3%)
.6. Statistical analyses
As a ﬁrst-in-human study, the trial was designed to provide pre-
iminary safety and immunogenicity data to support subsequent
esting in age-descending studies. The sample size allowed for
ecognition of unacceptable toxicity rates occurring at a frequency
f 10% or higher. The probability of observing at least one event
mong the twelve subjects in each dose cohort was  72% if the true
ttack rate of that event were 10%.
To investigate the fold-rise in IgG, IgA and neutralizing anti-
ody responses from baseline to one month post-3rd injection in
ach treatment group, the non-parametric signed-rank test was
sed [20], setting the null hypothesis to be H0: Ratio = 1 versus the
lternative H1: Ratio /= 1. To investigate whether there was  a sig-
iﬁcant trend in the proportions of subjects with ALS responses
ith increasing dose, the Chochran–Armitage test was used [21].
. Results
.1. Study population
A total of 48 participants were enrolled; 25 female and 23 male.
edian age was 34 years (range 19–44 years). Twelve participants
ach were randomized to receive placebo or 10 g, 30 g or 60 g
f the P2-VP8 subunit vaccine. All participants in the vaccine arms
eceived at least two study injections, and all 12 participants in the
0 g arm received all three study injections. Ten participants in
he placebo arm received all three study injections, one received
wo injections and another received one injection. Injections in
ne placebo recipient were discontinued after the ﬁrst vaccination
ue to moderate induration at the injection site, as required by
he protocol. The reasons for incomplete injection series for the
wo participants in the vaccination arms who received only two
njections were assessed unrelated to study injections.
.2. Safety
Overall, the vaccine was well-tolerated at all three dose levels,
nd no safety signals were identiﬁed.Only one participant experienced an objective site reaction
reater than mild, and that volunteer received placebo (Table 1).
ne vaccine recipient each in the 10 and 60 g cohorts complained
able 3
eutralizing antibody response rate to rotavirus strains (>four-fold increase 28 days after
Strain P type 10 g 30 g 
Response rate
%  (95% CI)
GMT
(95% CI)
Response Ra
%  (95% CI)
Wa 8 67 (35, 90) 670 (335, 1341) 42 (15, 72) 
89–12  8 83 (52, 98) 1792 (869, 3697) 67 (35, 90) 
P  8 58 (28, 85) 751 (438, 1282) 67 (35, 90) 
WI61  8 42 (15, 72) 1344 (740–2441) 67 (35, 90) 
DS1  4 0 (0, 26) 212 (140, 321) 50 (21, 79) 
SC2  6 8 (0, 38) 258 (166–401) 17 (2, 48) 
ST3  6 0 (0, 26) 97 (54, 177) 8 (0, 38) 
BrB  6 0 (0, 26) 331 (181–605) 25 (6, 57)  (2015) 3766–3772 3769
of greater than mild pain/tenderness; no participant in the 30 g
cohort reported greater than mild pain/tenderness.
Similarly, systemic reactions were relatively uncommon and
generally restricted to mild (Table 1). No volunteers experienced
severe reactions, and moderate reactions were limited to fatigue
in one volunteer in each of the groups receiving placebo, 10 g or
60 g. None of the volunteers experienced fever during the 7 days
following study injections.
The adverse event data through 28 days after completion
of study injections are summarized in Table 2. No volunteers
experienced a serious adverse event through 28 days follow-
ing completion of study injections, and the only severe adverse
event was  assessed as unrelated to receipt of vaccine (back
pain secondary to trauma). There were no discernible trends in
adverse events or safety laboratory values, which included basic
clinical hematology and chemistry to evaluate liver and renal
function.
3.3. IgG and IgA antibody responses
Sera were assessed for IgG and IgA responses to the P2-VP8
antigen by ELISA (Figs. 1 and 2, respectively) at baseline and one
month after each of the three study injections. Almost all vac-
cine recipients demonstrated greater than four-fold rise in IgG and
IgA response to P2-VP8 antigen by ELISA after three vaccinations:
only one vaccine recipient did not demonstrate an IgG response
(in the 30 g group) and all vaccine recipients demonstrated IgA
responses. There was a steady rise in both IgA and IgG geomet-
ric mean titers (GMTs) after each vaccination, with a statistically
signiﬁcant increase (p = 0.0005) over baseline one month after the
third vaccination in all treated groups. No changes in IgG and IgA
GMTs were observed in the placebo group
3.4. Neutralizing antibody responses
Sera were assessed for neutralizing antibodies to the homol-
ogous Wa strain (Fig. 3) at baseline and one month after each
of the three study injections, as well as several VP4 homolo-
gous and heterologous strains at baseline and after the third dose
(Day 84, Table 3). About half of vaccine recipients demonstrated
a four-fold or greater neutralizing antibody response to Wa,  with
clear increases in GMTs for all three dose levels at one month
post-third study injection (Day 84) compared to pre-vaccination
levels (p < 0.002). Of particular interest, of the 12 vaccine recipi-
ents (at any dose level) with low baseline titers (<100), 10 (83%)
demonstrated a >four-fold increase in neutralizing antibody; ﬁve
of these 12 were in the 60 g group, all of whom demonstratedate baseline titers (100–500) and the ﬁve participants with high
baseline titers (>500), 12 (63%) and none, respectively, mounted a
four-fold response.
 3rd dose) and geometric mean titer (GMT) 28 days after third study injection.
60 g
te GMT
(95% CI)
Response rate
%  (95% CI)
GMT
(95% CI)
695 (402, 1201) 58 (28, 85) 828 (493, 1393)
2040 (1065, 3907) 83 (52, 98) 2906 (1661, 5082)
886 (429, 1831) 83 (52, 98) 1509 (738, 3086)
1498 (862–2605) 83 (52, 98) 2507 (1149-5469)
202 (141, 291) 58 (28, 85) 407 (219, 755)
390 (282–537) 25 (6, 57) 201 (136-298)
88 (59, 131) 17 (2, 48) 65 (43, 99)
262 (177–387) 25 (6, 57) 117 (71–192)
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 EIA ti
t
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l
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d
tFig. 1. Anti-P2-VP8 IgG
Neutralizing antibody responses to other P[8] rotavirus strains
ested were robust and comparable to the vaccine homologous Wa
train. However responses were moderate to P[4] strains and fairly
imited to P[6] strains, which correlates well with the level of anti-
enic relatedness among these antigens [16,22] (Table 3).
.5. Antibody in lymphocyte supernatant responses
Antibodies were assessed to P2-VP8 in ALS at baseline and 7 days
fter the ﬁrst study injection (Fig. 4). None of the participants had
etectable ALS at baseline. There was a steady rise in proportion
f participants with detectable IgA responses 7 days after the ﬁrst
ose of vaccine from lowest (33.3%) to highest (66.7%) dose level,
hough the trend was not statistically signiﬁcant.
Fig. 2. Anti-P2-VP8 IgA EIA titers and response rates.
4. Discussion
Live oral rotavirus vaccines have recently been recommended
for use in developing countries by the World Health Organization
even though their efﬁcacy against severe disease in these popu-
lations (∼50%) is lower than in developed countries [1,2,23]. This
ﬁnding is neither rotavirus vaccine strain speciﬁc (it is found with
both globally licensed vaccines), nor unique to rotavirus vaccines
[3]. The diminished efﬁcacy of both viral and bacterial live oral
vaccines among developing country populations is believed to be
multifactorial and not easily overcome. Parenteral vaccines may
circumvent the factors associated with diminished protection in
these populations and potentially offer an enhanced level of pro-
tection. Additional beneﬁts of this approach include the ability
ters and response rates.
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nFig. 3. Neutralizing antibody
o combine parenteral vaccines, such as the P2-VP8 vaccine, with
xisting Expanded Programme on Immunization (EPI) vaccines to
acilitate vaccine uptake and reduce costs [24].
Our efforts to develop a non-replicating rotavirus vaccine
ocused on utilizing a truncated protein that contains most, if not
ll, of the neutralizing epitopes expressed in the virus VP8, a cleav-
ge product of the VP4 structural protein [25]. Selectively deleting
ortions of this protein rendered it soluble, thereby greatly enhanc-
ng yield and simplifying puriﬁcation. The yields obtained from the
treamlined manufacturing process (approximately 200 mg/liter)
romise to result in a vaccine with a very low cost of goods The P2
ig. 4. Antibody to P2-VP8 in lymphocyte supernatant 7 days after the ﬁrst vacci-
ation. and responses to Wa strain.
universal helper T cell epitope was  fused to the shortened VP8 pro-
tein to enhance immunogenicity, which has also been tested with
other vaccine constructs [26–28].
The P2-VP8 subunit vaccine was  very well tolerated and demon-
strated promising immunogenicity. Binding antibody responses
were almost universally induced, and IgA responses to the P2-VP8
were demonstrated in all vaccinees, at all dose levels. It is impor-
tant to note that previous assessment of IgA responses as a possible
correlate of protection has been based on IgA assays using antigens
from whole virus lysates, presumed to be predominantly VP6 [29],
and no inferences about whether VP8-speciﬁc responses are mean-
ingful in terms of protection can be made at this stage. The ALS IgA
responses demonstrated in the majority of participants receiving
the highest vaccine dose are also encouraging.
Immunization induced respectable concentrations of neutral-
izing antibody, albeit not as ubiquitous as the binding antibody
responses. Response rates were greatly dependent on baseline
titers, with those participants possessing low baseline titers
demonstrating much higher response rates compared to subjects
with intermediate or high titers. As expected, the most robust
responses were to the strains that express the P[8] antigen, includ-
ing the Wa  strain from which the vaccine is derived, 89–12 (also
a G1P[8] strain), and the P and WI61 strains, which are het-
erologous with respect to the VP7 G glycoprotein antigen. The
less robust responses to the P[4] strains and meager responses
to the P[6] strains raise the question of whether a multivalent
vaccine, including subunits from these other strains would be nec-
essary for a vaccine to be efﬁcacious in diverse geographic areas.
Although P[8] strains constitute the majority of strains identiﬁed
globally, strains expressing P[4] constitute an appreciable pro-
portion of strains identiﬁed in both Africa and Asia (up to 20%),
while P[6] strains represent as much as 30% of clinical isolates in
Africa [30–32].
Whether or how the induced antibodies reach the intestinal
mucosal at protecting concentrations will be difﬁcult to assess.
There is circumstantial evidence from human and animal research
to support that possibility. To address this indirectly, we are plan-
ning a test of concept to assess whether immunization with the
P2-VP8 subunit vaccine, which induces respectable concentrations
of neutralizing antibody to the 89–12, the progenitor strain of
Rotarix, impacts shedding of Rotarix, as a proxy of efﬁcacy.
Undoubtedly, the participants in this study had previously
experienced repeated exposure to rotavirus, and the promising
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esponses could be driven by anamnestic responses following nat-
ral exposure to live virus. However, participants generally had
elatively low binding antibody concentrations at baseline, and the
inetics of the responses, for both binding and neutralizing anti-
odies, are not characteristic of anamnestic responses. The critical
ext test for the vaccine will be to evaluate its safety and immuno-
enicity in the target population, which is immunologically naïve
nfants residing in a developing country. To accomplish this goal,
 phase I/II descending age, dose-escalation study in South African
oddlers and infants has been initiated.
unding
The authors would like to acknowledge the contributions of the
ill & Melinda Gates Foundation, which provides ﬁnancial support
o PATH’s Non-replicating Rotavirus Vaccine Project. The funder
ad no role in the design and conduct of the study; collection, man-
gement, analysis, and interpretation of the data; or preparation,
eview, or approval of the manuscript.
onﬂicts of interest
J.W.B is a shareholder in Merck & Co., Inc. (Whitehouse Station,
J). J.W.B. is currently employed at Takeda Vaccines, Inc., but dur-
ng the conduct of the trial and drafting of this manuscript was
mployed at PATH.
The Laboratory for Specialized Clinical Studies, Division of Infec-
ious Diseases at the Cincinnati Children’s Hospital Medical Center
as laboratory service agreements with Merck & Co, GlaxoSmithK-
ine and Sanoﬁ to provide testing for rotavirus vaccines.
A.D.F., C.H., L.D., J.F., G.R., and S.C.–No conﬂict.
cknowledgments
We thank Barbara Deneari and Alicia Cage for leading the clinical
esearch staff at the study clinic. We  also thank Allison Stanﬁll and
ophie Haralson for critical administrative support for the trial.
eferences
[1] Yen C, Tate JE, Patel MM,  Cortese MM,  Lopman B, Fleming J, et al. Rotavirus
vaccines: update on global impact and future priorities. Hum Vaccines
2011;7:1282–90.
[2] Jiang V, Jiang B, Tate J, Parashar UD, Patel MM.  Performance of rotavirus vaccines
in  developed and developing countries. Hum Vaccines 2010;6:532–42.
[3] Pasetti MF, Simon JK, Sztein MB,  Levine MM.  Immunology of gut mucosal vac-
cines. Immunol Rev 2011;239:125–48.
[4] Jiang B, Gentsch JR, Glass RI. Inactivated rotavirus vaccines: a priority for accel-
erated vaccine development. Vaccine 2008;26:6754–8.
[5] Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection
against rotavirus disease: an overview. Clin Infect Dis: Off Publ Infect Dis Soc
Am 2002;34:1351–61.
[6] Westerman LE, McClure HM,  Jiang B, Almond JW,  Glass RI. Serum IgG medi-
ates mucosal immunity against rotavirus infection. Proc Natl Acad Sci U S A
2005;102:7268–73.
[7] Wang Y, Azevedo M,  Saif LJ, Gentsch JR, Glass RI, Jiang B. Inactivated
rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine
2010;28:5432–6.
[8] Johansen K, Schroder U, Svensson L. Immunogenicity and protective efﬁcacy of
a  formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vac-
cine 2003;21:368–75.
[ (2015) 3766–3772
[9] Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L,
et  al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a
one-dose regimen induce protective immunity in mice. Vaccine 2008;26:
4594–601.
10] Angel J, Franco MA,  Greenberg HB. Rotavirus vaccines: recent developments
and  future considerations. Nat Rev Microbiol 2007;5:529–39.
11] Appaiahgari MB,  Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari
N,  et al. Transplacental rotavirus IgG interferes with immune response to
live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine 2014;32:
651–6.
12] Ramachandran M,  Vij A, Kumar R, Das BK, Gentsch JR, Bhan MK, et al. Lack of
maternal antibodies to P serotypes may predispose neonates to infections with
unusual rotavirus strains. Clin Diagn Lab Immunol 1998;5:527–30.
13] Ray PG, Kelkar SD, Walimbe AM,  Biniwale V, Mehendale S. Rotavirus
immunoglobulin levels among Indian mothers of two socio-economic groups
and occurrence of rotavirus infections among their infants up to six months. J
Med  Virol 2007;79:341–9.
14] Dunn SJ, Fiore L, Werner RL, Cross TL, Broome RL, Ruggeri FM,  et al. Immuno-
genicity, antigenicity, and protection efﬁcacy of baculovirus expressed VP4
trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus. Arch Virol
1995;140:1969–78.
15] Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM,  et al.
Effects of antibody to rotavirus on protection of adults challenged with a human
rotavirus. J Infect Dis 1989;159:79–88.
16] Wen  X, Cao D, Jones RW,  Li J, Szu S, Hoshino Y. Construction and characterization
of  human rotavirus recombinant VP8* subunit parenteral vaccine candidates.
Vaccine 2012;30:6121–6.
17] Wen  X, Wen  K, Cao D, Li G, Jones RW,  et al. Inclusion of a universal tetanus
toxoid CD4(+) T cell epitope P2 signiﬁcantly enhanced the immunogenic-
ity  of recombinant rotavirus DeltaVP8* subunit parenteral vaccines. Vaccine
2014;32:4420–7.
18] Knowlton DR, Spector DM,  Ward RL. Development of an improved method for
measuring neutralizing antibody to rotavirus. J Virol Methods 1991;33:127–34.
19] Chang HS, Sack DA. Development of a novel in vitro assay (ALS assay) for
evaluation of vaccine-induced antibody secretion from circulating mucosal
lymphocytes. Clin Diagn Lab Immunol 2001;8:482–8.
20] Wilcoxon F. Individual comparisons by ranking methods. Biom Bull
1945;1:80–3.
21] Armitage P. Tests for linear trends in proportions and frequencies. Biometrics
1955;11:375–86.
22] Larralde G, Flores J. Identiﬁcation of gene 4 alleles among human rotaviruses
by  polymerase chain reaction-derived probes. Virology 1990;179:469–73.
23] WHO. Rotavirus vaccines: WHO  position paper—January 2013. 2013.
24] WHO. The expanded programme on immunization 〈http://www.who.int/
immunization/programmes systems/supply chain/beneﬁts of immunization/
en/〉; 2013 [accessed 01.04.15 and last updated 01.12.13].
25] Estes MK,  Graham DY, Mason BB. Proteolytic enhancement of rotavirus infec-
tivity: molecular mechanisms. J Virol 1981;39:879–88.
26] Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavec-
chia A. Universally immunogenic T cell epitopes: promiscuous binding to
human MHC  class II and promiscuous recognition by T cells. Eur J Immunol
1989;19:2237–42.
27] Ahlborg N, Ling IT, Holder AA, Riley EM.  Linkage of exogenous T-cell epi-
topes to the 19-kilodalton region of Plasmodium yoelii merozoite surface
protein 1 (MSP1(19)) can enhance protective immunity against malaria and
modulate the immunoglobulin subclass response to MSP1(19). Infect Immun
2000;68:2102–9.
28] Falugi F, Petracca R, Mariani M,  Luzzi E, Mancianti S, Carinci V, et al. Ratio-
nally designed strings of promiscuous CD4(+) T cell epitopes provide help to
Haemophilus inﬂuenzae type b oligosaccharide: a model for new conjugate vac-
cines. Eur J Immunol 2001;31:3816–24.
29] Padilla-Noriega L. Elisas for rotavirus diagnosis, typing, and analysis of anti-
body response. In: Abuelzein E, editor. Trends in immunolabelled and related
techniques. 2012. pp. 227–42.
30] Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes
and its implication for the development and implementation of an effective
rotavirus vaccine. Rev Med  Virol 2005;15:29–56.
31] Seheri M, Nemarude L, Peenze I, Netshifhefhe L, Nyaga MM,  Ngobeni HG, et al.
Update of rotavirus strains circulating in Africa from 2007 through 2011. Pedi-
atr Infect Dis J 2014;33(Suppl 1):S76–84.
32] Todd S, Page NA, Duncan Steele A, Peenze I, Cunliffe NA. Rotavirus strain types
circulating in Africa: review of studies published during 1997–2006. J Infect
Dis 2010;202(Suppl):S34–42.
